Subtype
Malignant Urinary System Neoplasm
CI-CAN-00001187Explore in graph →
888 active trials28 approved drugs109 evidence items
- NCIt
- C9297
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001187Explore in graph →
Clinical trials
3,853 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (556)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07314723 | 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer | recruiting | Phase 2 | 90 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Jan 2, 2026 | clinicaltrials |
| NCT07279597 | A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer | not yet recruiting | Phase 2 | 45 | Tongji HospitalOTHER | 0 | Dec 19, 2025 | clinicaltrials |
| NCT04863885 | Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients | active not recruiting | Phase 1 / Phase 2 | 46 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06263153 | Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy | recruiting | Phase 2 | 24 | Yuanquan YangOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06210490 | A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery | recruiting | Phase 2 | 60 | Peking University First HospitalOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT07277972 | Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy | not yet recruiting | Phase 2 | 36 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Dec 11, 2025 | clinicaltrials |
| NCT05363631 | Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab | active not recruiting | Phase 1 / Phase 2 | 55 | Mohammed MilhemOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT05912816 | Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients | recruiting | Phase 2 | 20 | RenJi HospitalOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT06091124 | Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma(NEOBLAST) | recruiting | Phase 2 | 22 | RenJi HospitalOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT04974671 | Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma | recruiting | Phase 2 | 30 | Yale UniversityOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07261592 | Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer | not yet recruiting | Phase 1 / Phase 2 | 29 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07257718 | The Combined Role of FAPI PET and Liquid Biopsy in the Staging and Clinical Management of Bladder Cancer - FUTURE Trial(FUTURE) | not yet recruiting | Phase 2 | 262 | Chiti ArturoOTHER | 0 | Dec 2, 2025 | clinicaltrials |
| NCT05975307 | Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation(BCIRT-01) | active not recruiting | Phase 2 | 71 | Sun Yat-sen UniversityOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT05770037 | DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT03697850 | Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy(BladderSpar) | active not recruiting | Phase 2 | 79 | UNICANCEROTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04428554 | Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy(BLAD-RAD01) | recruiting | Phase 2 | 130 | Institut Claudius RegaudOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04386746 | Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer(GEMDOCE) | active not recruiting | Phase 2 | 27 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06601296 | Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer(SPARK) | recruiting | Phase 2 | 15 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT02420847 | Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery | active not recruiting | Phase 1 / Phase 2 | 57 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04074967 | Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab | active not recruiting | Phase 1 / Phase 2 | 70 | Dan ZandbergOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT07225374 | Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC | recruiting | Phase 2 | 48 | Samsung Medical CenterOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT04724018 | Sacituzumab Govitecan Plus EV in Metastatic UC | recruiting | Phase 1 / Phase 2 | 106 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT06005818 | Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)(MRD GATE RCC) | recruiting | Phase 2 | 100 | University of Alabama at BirminghamOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT07218692 | RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy | not yet recruiting | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT03022825 | QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer | active not recruiting | Phase 2 / Phase 3 | 190 | ImmunityBio, Inc.INDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT06829823 | Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer | not yet recruiting | Phase 2 | 20 | ImmunityBio, Inc.INDUSTRY | 0 | Oct 16, 2025 | clinicaltrials |
| NCT03978624 | Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer | active not recruiting | Phase 2 | 20 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT05931393 | Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC) | recruiting | Phase 2 | 18 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT00722228 | Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors | recruiting | Phase 1 / Phase 2 | 50 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT03438708 | Prior Axitinib as a Determinant of Outcome of Renal Surgery(PADRES) | active not recruiting | Phase 2 | 22 | University of California, San DiegoOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05148546 | Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer(NESCIO) | active not recruiting | Phase 2 | 69 | The Netherlands Cancer InstituteOTHER | 2 | Sep 30, 2025 | clinicaltrials |
| NCT05965856 | A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 52 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT04678362 | TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma(TALASUR) | recruiting | Phase 2 | 50 | Centre Francois BaclesseOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07184021 | Neoadjuvent Dose-dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer(No Acronym) | not yet recruiting | Phase 2 | 30 | Assiut UniversityOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT05329532 | Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer(ModiFY) | recruiting | Phase 1 / Phase 2 | 168 | Scancell LtdINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT03647163 | Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 33 | Vyriad, Inc.INDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT07172386 | Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC | recruiting | Phase 2 | 40 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT07175480 | PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk(Perfumer) | recruiting | Phase 2 | 30 | Jinling Hospital, ChinaOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT05845814 | A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) | active not recruiting | Phase 1 / Phase 2 | 390 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 10, 2025 | clinicaltrials |
| NCT00082706 | Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant | active not recruiting | Phase 2 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06302569 | Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma(REPRINT) | recruiting | Phase 2 | 23 | Giuseppe ProcopioOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT07159191 | Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma | not yet recruiting | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 0 | Sep 8, 2025 | clinicaltrials |
| NCT05318573 | A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 120 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT06255223 | A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy | recruiting | Phase 2 | 35 | Jinling Hospital, ChinaOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06571708 | Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)(NeoSTOP-IT) | recruiting | Phase 2 | 36 | Columbia UniversityOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT05879653 | Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD) | recruiting | Phase 2 | 30 | Kyoto University HospitalOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT06127238 | Study of ST-1898 in Advanced Renal Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 90 | Beijing Scitech-Mq Pharmaceuticals LimitedINDUSTRY | 1 | Aug 24, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 2, 2026source: clinicaltrials